

## Product Datasheet

# IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated (orb1960404)

<b>Description</b>	Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
<b>Storage</b>	-20°C
<b>Tag</b>	C-His
<b>Note</b>	For research use only
<b>Purity</b>	98.00%
<b>MW</b>	21.14 kDa (predicted). Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.
<b>Uniprot ID</b>	<b>A0A2K5UDJ4</b>
<b>Expiration Date</b>	6 months from date of receipt.

**Biorbyt Ltd.**

7 Signet Court, Swann's Road,  
Cambridge, CB5 8LA, United Kingdom  
Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)  
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

**Biorbyt LLC.**

68 TW Alexander Drive,  
Durham, NC, 27713, United States  
Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)  
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)